Ileana L. Piña MD, MPH, FAHA, FACC
Quality Officer for the Cardiovascular Line, Thomas Jefferson University/Sidney Kimmel College of Medicine, Philadelphia, Pennsylvania; Clinical Professor, Central Michigan University, Mount Pleasant, MichiganIleana L. Piña, MD, MPH, is Quality Officer for the Cardiovascular Line at Thomas Jefferson University/Sidney Kimmel College of Medicine in Philadelphia, Pennsylvania. She is Clinical Professor at Central Michigan University in Mount Pleasant and is Adjunct Professor of Epidemiology and Biostatistics, Population and Quantitative Health Sciences, at Case Western University, Cleveland, Ohio. Dr. Piña also serves as Senior Fellow and Medical Officer to the Food and Drug Administrations’ Center for Devices and Radiological Health.
Dr. Piña’s research interests include transition of care in heart failure patients and the role of natriuretic peptide–guided management for patients hospitalized for heart failure, biomarkers of myocardial stress and fibrosis in chronic heart failure, and heart failure differences by sex. She has been actively involved in gender, racial, and ethnic issues in healthcare delivery. She is the author/co-author of more than 250 publications.
Disclosures
- Advisory boards: Vifor Pharma (acquired by CSL in 2022), modest; AstraZeneca, modest
Recent Contributions to PracticeUpdate:
- Effects of Sotagliflozin on Health Status in Patients With Worsening Heart Failure
- 2023 Top Story in Cardiology: It May Have Gone Unnoticed… A Commentary on the Recent FDA Approval of Empagliflozin for CKD
- Managing Cardiovascular Sequelae in Long COVID-19
- HFpEF: Pathways, Mechanisms, and Emerging Trends
- Dapagliflozin and Other Therapies for HFrEF
- HFrEF: Effective Treatment Options
- Heart Failure and Cardiomyopathies
- HFpEF and COVID at ACC 2023
- Cardiomyopathy and HF at ACC 2023
- Patient Characteristics, Outcomes, and Effects of Dapagliflozin According to the Duration of Heart Failure